Novo Nordisk already has a solid pipeline of obesity drugs, but the launch of a new research center in Seattle should further accelerate early stage R&D in the field - and there is a very clear reason the US city was chosen as the site, says the group's CSO.
Camilla Harder Hartvig has moved from senior positions with Novartis and AstraZeneca to becoming the head of Allergan’s Nordic business - and the task of having to interact with healthcare bodies on behalf of her new company presents brand new challenges.
The Chairman of industry association Dansk Biotek is disappointed to see AbbVie halting development of the Action Pharma-developed asset, ABT-719, but as is the case with most biotech deals there was a high risk associated with the agreement, he says.
While opportunities for raising capital in the Danish life science industry are in decline, the biotech and drug companies are still among the best in Europe when it comes to the number of candidate drugs under development.
Following failed phase II studies, AbbVie has decided to end development of an asset the US-based group bought from Denmark-based biotech Action Pharma in one of the biggest biotech deals in the history of Danish business.
Novo Nordisk’s science chief followed last week’s FDA panel meeting via live cast along with hundreds of Novo employees, and it was a much more pleasant experience than on the two previous occasions. Find out why the CSO is so sure the company will make it big on the US obesity market.
Following the reinforcement of the company’s financial foundation, Genmab’s CEO will now implement a much more commercial mindset in all aspects of drug development and the company will possibly begin to market drugs on its own.
FDA has already rejected Genzyme’s MS drug Lemtrada once, but the company’s executives in charge of the MS area believe in approval second time around. Major bank Barclays is less optimistic. A new verdict is expected to fall before the close of 2014.
Many people dream of it, but few have actually tried it in Denmark – selling something to Big Pharma. There is one crucial factor if you want to increase your chances, says Allan Jensen, who has worked for the Danish biotech company Symphogen and the US drug giant Pfizer.
The FDA has revealed the agenda for Thursday’s panel meeting to discuss Novo Nordisk's candidate drug to treat obesity. There are no major surprises, says an analyst, who identifies the biggest obstacle for approval of the potential blockbuster.
According to a sector analyst, gene analysis company Exiqon finds itself in difficult times and there is no light at the end of the tunnel this year, as the company will struggle to meet its full-year guidance.
Nordea believes that Novo Nordisk is heading into an easier second half of the year in which the major event will be an FDA decision on the Danish group’s obesity contender – a decision that should go Novo’s way, the bank says.
Novo Nordisk CSO Mads Krogsgaard Thomsen admits that it has been more difficult than expected to deliver within the now abandoned inflammation unit. The company’s four attempts all missed the target and the alternative to abandoning the entire project would have been a major acquisition.
The biggest acquisition in the history of the company led to Eli Lilly’s intense focus on oncology drugs, which is now nearing its climax. The US company’s Scandinavian head has talked to MedWatch about the crown jewel of the group’s pipeline and the ubiquitous presence of a certain rival.
Danish diabetes giant Novo Nordisk has chosen to discontinue all its R&D activities within inflammatory disorders to focus fully on the discovery and development of diabetes drugs. The closure affects 400 employees.
An employee’s level of commitment can be affected by circumstances in the family, such as disease – and the company should be sensitive to that. But if people are down-right uncommitted, the corporate culture is so strong that it will gradually expel them. Lars Rebien, at the peak of his career, spoke to Medwatch about the unique Novo spirit, about failing politicians, and about growing softer.
Gitte Pedersen’s career began in Novo Nordisk and the Danish drug giant led her to the US, where she is now CEO and co-founder of a diagnostics company in Manhattan – a career that is partly formed by a past peopled by engineers and women’s rights activists.